|
1
|
Stewart BW and Wild CP: World Cancer
Report 2014IARC; Lyon, France: pp. 839–851. 2014
|
|
2
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamran SC, Hong TS and Wo JY: Advances in
the management of gastric and gastroesophageal cancers. Curr Oncol
Rep. 18:132016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee YY and Derakhshan MH: Environmental
and lifestyle risk factors of gastric cancer. Arch Iran Med.
16:358–365. 2013.PubMed/NCBI
|
|
5
|
Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi
ST, Siu HC, Deng S, Chu KM, Law S, et al: Whole-genome sequencing
and comprehensive molecular profiling identify new driver mutations
in gastric cancer. Nat Genet. 46:573–582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Venerito M, Vasapolli R, Rokkas T,
Delchier JC and Malfertheiner P: Helicobacter pylori, gastric
cancer and other gastrointestinal malignancies. Helicobacter. 22
(Suppl 1):2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoon H and Kim N: Diagnosis and management
of high risk group for gastric cancer. Gut Liver. 9:5–17. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aurello P, Sagnotta A, Terrenato I,
Berardi G, Nigri G, D'Angelo F and Ramacciato G: Oncologic value of
laparoscopy-assisted distal gastrectomy for advanced gastric
cancer: A systematic review and meta-analysis. J Minim Access Surg.
12:199–208. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen K, Xu XW, Zhang RC, Pan Y, Wu D and
Mou YP: Systematic review and meta-analysis of laparoscopy-assisted
and open total gastrectomy for gastric cancer. World J
Gastroenterol. 19:5365–5376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Janunger KG, Hafström L and Glimelius B:
Chemotherapy in gastric cancer: A review and updated meta-analysis.
Eur J Surg. 168:597–608. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Othman MO and Wallace MB: Endoscopic
mucosal resection (EMR) and endoscopic submucosal dissection (ESD)
in 2011, a Western perspective. Clin Res Hepatol Gastroenterol.
35:288–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liang L, Fang JY and Xu J: Gastric cancer
and gene copy number variation: Emerging cancer drivers for
targeted therapy. Oncogene. 35:1475–1482. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Valentini V and Cellini F: Radiotherapy in
gastric cancer: A systematic review of literature and new
perspectives. Expert Rev Anticancer Ther. 7:1379–1393. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wagner AD, Unverzagt S, Grothe W, Kleber
G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev. CD0040642010.PubMed/NCBI
|
|
15
|
Stordal B and Davey M: Understanding
cisplatin resistance using cellular models. IUBMB Life. 59:696–699.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jacobsen C and Honecker F: Cisplatin
resistance in germ cell tumours: Models and mechanisms. Andrology.
3:111–121. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang SM, Huang C, Li XF, Yu MZ, He Y and
Li J: miR-21 confers cisplatin resistance in gastric cancer cells
by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun XP, Dong X, Lin L, Jiang X, Wei Z,
Zhai B, Sun B, Zhang Q, Wang X, Jiang H, et al: Up-regulation of
survivin by AKT and hypoxia-inducible factor 1α contributes to
cisplatin resistance in gastric cancer. FEBS J. 281:115–128. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang M, Shan X, Zhou X, Qiu T, Zhu W, Ding
Y, Shu Y and Liu P: miR-1271 regulates cisplatin resistance of
human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and
BCL2. Anticancer Agents Med Chem. 14:884–891. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu W, Wang S, Chen Q, Zhang Y, Ni P, Wu X,
Zhang J, Qiang F, Li A, Røe OD, et al: TXNL1-XRCC1 pathway
regulates cisplatin-induced cell death and contributes to
resistance in human gastric cancer. Cell Death Dis. 5:e10552014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gloerich M, ten Klooster JP, Vliem MJ,
Koorman T, Zwartkruis FJ, Clevers H and Bos JL: Rap2A links
intestinal cell polarity to brush border formation. Nat Cell Biol.
14:793–801. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu JX, Zhang DG, Zheng JN and Pei DS:
Rap2a is a novel target gene of p53 and regulates cancer cell
migration and invasion. Cell Signal. 27:1198–1207. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang D, Duan H, Huang H, Tong X, Han Y,
Ru G, Qu L, Shou C and Zhao Z: Cisplatin resistance in gastric
cancer cells is associated with HER2 upregulation-induced
epithelial-mesenchymal transition. Sci Rep. 6:205022016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kramer N, Walzl A, Unger C, Rosner M,
Krupitza G, Hengstschläger M and Dolznig H: In vitro cell migration
and invasion assays. Mutat Res. 752:10–24. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Erba E, Ubezio P, Broggini M, Ponti M and
D'Incalci M: DNA damage, cytotoxic effect and cell-cycle
perturbation of Hoechst 33342 on L1210 cells in vitro. Cytometry.
9:1–6. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Redondo-Blanco S, Fernández J,
Gutiérrez-Del-Río I, Villar CJ and Lombó F: New insights toward
colorectal cancer chemotherapy using natural bioactive compounds.
Front Pharmacol. 8:1092017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zitvogel L, Apetoh L, Ghiringhelli F and
Kroemer G: Immunological aspects of cancer chemotherapy. Nat Rev
Immunol. 8:59–73. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Meeks JJ, Bellmunt J, Bochner BH, Clarke
NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T,
et al: A systematic review of neoadjuvant and adjuvant chemotherapy
for muscle-invasive bladder cancer. Eur Urol. 62:523–533. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sui X, Chen R, Wang Z, Huang Z, Kong N,
Zhang M, Han W, Lou F, Yang J, Zhang Q, et al: Autophagy and
chemotherapy resistance: A promising therapeutic target for cancer
treatment. Cell Death Dis. 4:e8382013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Terek RM, Schwartz GK, Devaney K, Glantz
L, Mak S, Healey JH and Albino AP: Chemotherapy and P-glycoprotein
expression in chondrosarcoma. J Orthop Res. 16:585–590. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gibalová L, Sereš M, Rusnák A, Ditte P,
Labudová M, Uhrík B, Pastorek J, Sedlák J, Breier A and Sulová Z:
P-glycoprotein depresses cisplatin sensitivity in L1210 cells by
inhibiting cisplatin-induced caspase-3 activation. Toxicol In
Vitro. 26:435–444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu LZ, Zhou XD, Qian G, Shi X, Fang J and
Jiang BH: AKT1 amplification regulates cisplatin resistance in
human lung cancer cells through the mammalian target of
rapamycin/p70S6K1 pathway. Cancer Res. 67:6325–6332. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bauer JA, Kumar B, Cordell KG, Prince ME,
Tran HH, Wolf GT, Chepeha DB, Teknos TN, Wang S, Eisbruch A, et al:
Targeting apoptosis to overcome cisplatin resistance: A
translational study in head and neck cancer. Int J Radiat Oncol
Biol Phys. 69 (2 Suppl):S106–S108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu WK, Wang Z, Fong CC, Liu D, Yip TC, Au
SK, Zhu G and Yang M: Chemoresistant lung cancer stem cells display
high DNA repair capability to remove cisplatin-induced DNA damage.
Br J Pharmacol. 174:302–313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Okada T, Sinha S, Esposito I, Schiavon G,
López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M,
et al: The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT
by restraining Ras-MAPK signalling. Nat Cell Biol. 17:81–94. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sharma S, Santiskulvong C, Rao J,
Gimzewski JK and Dorigo O: The role of Rho GTPase in cell stiffness
and cisplatin resistance in ovarian cancer cells. Integr Biol
(Camb). 6:611–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cho HJ, Baek KE, Park SM, Kim IK, Nam IK,
Choi YL, Park SH, Im MJ, Choi J, Ryu J, et al: RhoGDI2 confers
gastric cancer cells resistance against cisplatin-induced apoptosis
by upregulation of Bcl-2 expression. Cancer Lett. 311:48–56. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Awasthi S, Sharma R, Yang Y, Singhal SS,
Pikula S, Bandorowicz-Pikula J, Singh SV, Zimniak P and Awasthi YC:
Transport functions and physiological significance of 76 kDa
Ral-binding GTPase activating protein (RLIP76). Acta Biochim Pol.
49:855–867. 2002.PubMed/NCBI
|
|
39
|
Stuckler D, Singhal J, Singhal SS, Yadav
S, Awasthi YC and Awasthi S: RLIP76 transports vinorelbine and
mediates drug resistance in non-small cell lung cancer. Cancer Res.
65:991–998. 2005.PubMed/NCBI
|
|
40
|
Vatsyayan R, Chaudhary P, Lelsani PC,
Singhal P, Awasthi YC, Awasthi S and Singhal SS: Role of RLIP76 in
doxorubicin resistance in lung cancer. Int J Oncol. 34:1505–1511.
2009.PubMed/NCBI
|
|
41
|
Wu R, Murali R, Kabe Y, French SW, Chiang
YM, Liu S, Sher L, Wang CC, Louie S and Tsukamoto H: Baicalein
targets GTPase-mediated autophagy to eliminate liver tumor
initiating stem cell-like cells resistant to mTORC1 inhibition.
Hepatology. 68:1726–1740. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhu WL, Hossain MS, Guo DY, Liu S, Tong H,
Khakpoor A, Casey PJ and Wang M: A role for Rac3 GTPase in the
regulation of autophagy. J Biol Chem. 286:35291–35298. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sirichanchuen B, Pengsuparp T and
Chanvorachote P: Long-term cisplatin exposure impairs autophagy and
causes cisplatin resistance in human lung cancer cells. Mol Cell
Biochem. 364:11–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kumar P, Zhang DM, Degenhardt K and Chen
ZS: Autophagy and transporter-based multi-drug resistance. Cells.
1:558–575. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang L, Zhu B, Wang S, Wu Y, Zhan W, Xie
S, Shi H and Yu R: Regulation of glioma migration and invasion via
modification of Rap2a activity by the ubiquitin ligase Nedd4-1.
Oncol Rep. 37:2565–2574. 2017. View Article : Google Scholar : PubMed/NCBI
|
